Erasca (ERAS)
NASDAQ:ERAS
Top Page
Erasca
(NASDAQ:ERAS)
Select Model
Select Model
Rating:55Neutral
Price Target:
$16.50
▲(12.47% Upside)
Action:ReiteratedDate:03/13/26
The score is most constrained by weak financial performance (no revenue, sizable losses, and ongoing cash burn), partially offset by strong technical momentum and positive corporate developments that extend the cash runway and highlight clinical progress. Valuation remains challenged due to negative earnings and no dividend support.
Positive Factors
Extended cash runway
The sizable, recent equity raise and reported cash balance materially extend liquidity into mid‑2029, providing durable funding for multi‑year clinical programs. This reduces near‑term financing pressure, allowing management to execute planned dose escalations and pivotal readouts without immediate dilution risk.
Negative Factors
No revenue, large losses
As a pre‑commercial biotech with material recurring losses, Erasca lacks operating cash inflows and depends on capital markets to fund operations. Persistent negative profitability creates ongoing dilution risk and constrains strategic optionality if clinical setbacks delay or negate commercialization prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended cash runway
The sizable, recent equity raise and reported cash balance materially extend liquidity into mid‑2029, providing durable funding for multi‑year clinical programs. This reduces near‑term financing pressure, allowing management to execute planned dose escalations and pivotal readouts without immediate dilution risk.
Read all positive factors
Erasca (ERAS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.97B
Dividend YieldN/A
Average Volume (3M)6.76M
Price to Earnings (P/E)―
Beta (1Y)1.93
Revenue GrowthN/A
EPS Growth45.66%
CountryUS
Employees103
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.10
Shares Outstanding310,799,560
10 Day Avg. Volume8,687,046
30 Day Avg. Volume6,757,213
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)3.24
Price to Sales (P/S)0.00
P/FCF Ratio-11.03
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.65K
Enterprise Value/Ebitda-39.12
Forecast
1Y Price Target
$17.33Price Target Upside18.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.44
Revenue Forecast (FY)N/A
Erasca Business Overview & Revenue Model
Company Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK...
How the Company Makes Money
null...
Erasca Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.11M | 0.00 | -3.73M | -2.64M | -829.00K |
| EBITDA | -128.30M | -153.28M | -121.31M | -240.16M | -121.94M |
| Net Income | -124.55M | -161.65M | -125.04M | -242.81M | -122.76M |
Balance Sheet | |||||
| Total Assets | 396.15M | 502.53M | 395.30M | 514.91M | 501.42M |
| Cash, Cash Equivalents and Short-Term Investments | 276.07M | 298.31M | 312.35M | 435.62M | 414.48M |
| Total Debt | 47.14M | 51.89M | 55.86M | 55.10M | 18.79M |
| Total Liabilities | 70.98M | 79.03M | 78.61M | 103.06M | 44.89M |
| Stockholders Equity | 325.17M | 423.50M | 316.69M | 411.85M | 456.53M |
Cash Flow | |||||
| Free Cash Flow | -95.58M | -131.98M | -102.99M | -119.81M | -98.48M |
| Operating Cash Flow | -95.45M | -109.42M | -101.22M | -103.26M | -79.60M |
| Investing Cash Flow | 100.42M | -156.62M | -91.22M | -71.08M | -64.59M |
| Financing Cash Flow | 1.10M | 240.70M | 1.29M | 98.08M | 439.40M |
Erasca Technical Analysis
Positive
14.67
Price Trends
12.50
Positive
7.90
Positive
4.81
Positive
Market Momentum
0.73
Positive
65.90
Neutral
70.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ERAS, the sentiment is Positive. The current price of 14.67 is above the 20-day moving average (MA) of 14.62, above the 50-day MA of 12.50, and above the 200-day MA of 4.81, indicating a bullish trend. The MACD of 0.73 indicates Positive momentum. The RSI at 65.90 is Neutral, neither overbought nor oversold. The STOCH value of 70.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ERAS.
Erasca Risk Analysis
Erasca disclosed 85 risk factors in its most recent earnings report. Erasca reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Erasca Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $1.18B | -5.93 | -27.17% | ― | ― | -103.95% | |
55 Neutral | $4.97B | -8.47 | -32.00% | ― | ― | 45.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $200.67M | -1.44 | -27.43% | ― | -41.53% | -11.32% | |
48 Neutral | $698.45M | ― | -14.25% | ― | ― | ― | |
47 Neutral | $1.24B | -13.39 | -42.90% | ― | ― | 17.23% |
* Healthcare Sector Average
ERAS
Erasca
15.99
14.51
980.41%
ARCT
Arcturus Therapeutics
7.06
-4.89
-40.92%
ARVN
Arvinas Holding Company
10.92
2.97
37.36%
OLMA
Olema Pharmaceuticals
14.17
10.03
242.27%
BCAX
Bicara Therapeutics Inc.
18.68
5.58
42.60%
Erasca Corporate Events
Financial DisclosuresPrivate Placements and Financing
Erasca extends cash runway after upsized public offering
Positive
Jan 29, 2026
On January 20, 2026, Erasca, Inc. reported that its preliminary, unaudited cash, cash equivalents and marketable securities totaled approximately $341.8 million as of December 31, 2025, and on January 23, 2026, the company closed an upsized public...
Business Operations and StrategyPrivate Placements and Financing
Erasca Announces Major Underwritten Public Equity Offering
Positive
Jan 22, 2026
On January 21, 2026, Erasca entered into an underwriting agreement with J.P. Morgan, Morgan Stanley, Jefferies and Evercore for an underwritten public offering of 22.5 million shares of common stock at $10.00 per share, with underwriters purchasin...
Business Operations and StrategyProduct-Related Announcements
Erasca Highlights Accelerated Progress in RAS-Targeted Trials
Positive
Jan 12, 2026
On January 12, 2026, Erasca updated its corporate presentation and announced clinical progress across its RAS-targeting franchise, highlighting that dose escalation in the Phase 1 AURORAS-1 trial of ERAS-0015 has been advancing faster than anticip...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.